Guanfacine Tablet, Extended Release
Product Images NDC 50090-7129

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 50090-7129). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing guanfacine plasma concentration (ng/mL) over time (hours) between extended-release and immediate-release formulations, both dosed at 1 mg once daily. The graph shows higher peak levels with immediate-release and more sustained levels with extended-release guanfacine over 24 hours.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC caused by various substances, including CYP3A4/5 inhibitors (Ketoconazole), CYP3A4 inducers (Rifampin), and other compounds like Fluconazole, Efavirenz, Oral Methylphenidate, and Lisdexamfetamine Dimesylate. The x-axis represents the change relative to reference from 0 to 5.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A forest plot chart showing the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for the interacting drugs Oral Methylphenidate and Lisdexamfetamine Dimesylate relative to a reference. The x-axis represents change relative to reference from 0.0 to 2.0, with plotted points and error bars for each parameter.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph depicting time to treatment failure in days on the x-axis and treatment failure percentage on the y-axis, comparing placebo and SPD503. The graph shows cumulative treatment failure rates over approximately 200 days for two groups, with placebo indicated by a solid line and SPD503 by a dashed line.*
FDA Label Image

Label Image (Lbl500907129)

Label Image (Lbl500907129)
Label for Guanfacine extended-release tablets, 3 mg strength, manufactured by A-S Medication Solutions. The label indicates the product contains 90 tablets per package, with each tablet containing 3 mg of guanfacine extended-release. Storage instructions specify keeping the product between 68 to 77 degrees Fahrenheit. Additional information includes the product number 2568-0 and the NDC 50090-7129.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of guanfacine hydrochloride showing its molecular arrangement with chlorine atoms and amide groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.